| Name | Title | Contact Details |
|---|
A publicly traded (OTC: CBSC) company providing innovative products and services in the ambulatory non-invasive cardiac monitoring space. CB Scientific, Inc., through its US and international subsidiaries, provides innovative products and services in the ambulatory non-invasive cardiac monitoring space. Our FDA and CE cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms, provide improved compliance for patients at risk of abnormal heart rhythms as well as more accurate information for physicians.
The Rhode Island Blood Center was founded in 1979 as a non-profit community blood center. Our goal is to ensure that all Rhode Islanders have immediate access to a safe and plentiful blood supply. The blood center achieves its goals by constantly
In 1993, a novel technology was invented by a team that included Jon Faiz Kayyem, PhD at The California Institute of Technology (CalTech). This invention combined nucleic acids and microelectronics to produce an electronic sensor for DNA detection. His invention was based on electrical detection of nucleic acids on a cassette based detection platform. Dr. Kayyem went on to found Clinical Micro Sensors, with the goal of translating this “eSensor” technology to disposable chips. Following several acquisitions of the technology, Dr. Kayyem became actively involved again in 2009, returning as an investor and then as CEO and Chairman of the Board. In 2009, a collaboration between Dr. Kayyem and Christopher Gleeson began. The two redefined the company strategy, and brought in a new board of directors, executive leadership team, and commercial management. In 2010, the company known at that time as Osmetech, was named GenMark Diagnostics and listed on NASDAQ. Mr. Gleeson remained an integral part of GenMark`s growth in the years that followed, serving as Chairman of the Board until his retirement in 2014. Dr. Kayyem currently serves as SVP, Research and Development.
Techreg Services is a Hillsborough, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Endotronix, a digital health medtech company, is developing an integrated platform to provide comprehensive, reimbursable health management tools for patients suffering from advanced heart failure. The Cordella™ Heart Failure System includes a cloud-based disease-management system and a breakthrough implantable wireless pulmonary artery pressure sensor. The seamlessly integrated system enables proactive management and early detection of worsening heart failure, which promotes ongoing therapeutic interventions to improve quality of life, reduce hospital readmissions, and lower care costs.